News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

Opinion|Videos|September 11, 2024

Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

Author(s)Karen O. Klein, MD, Jill Samis, MD , Aviva B. Sopher, MD, MS

Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.

Episodes in this series

3 KOLs are featured in this series.

EP. 1 Overview Of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 2 Diagnosis of Central Precocious Puberty and its Psychosocial Impact

3 KOLs are featured in this series.

EP. 3 Early Diagnosis and Treatment for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 4 Treatment Options for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 5 Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

3 KOLs are featured in this series.

EP. 6 Individualized Management of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 7 Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

3 KOLs are featured in this series.

EP. 8 Central Precocious Puberty in Male Patients

3 KOLs are featured in this series.

EP. 9 Recommendations and Outlook for Central Precocious Puberty

Video content above is prompted by the following:

What are common misconceptions regarding the timing of therapy initiation and discontinuation?
What has research shown regarding outcomes for initiating therapy before age 7 years or discontinuing therapy after age 12 years?
What consideration should clinicians give about the time to first menses after treatment cessation?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

4 Experts are featured in this series

RSV Prevention: Final Reflections and a Vision for the Future

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 20th 2026

4 Experts are featured in this series

RSV Prevention and Vaccine Hesitancy: Building Long-Term Communication

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 20th 2026

4 Experts are featured in this series

RSV Immunization Rates and Vaccine Hesitancy: Practical Strategies for Clinicians

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 13th 2026

4 Experts are featured in this series

RSV and the Challenge of Reinfection: Long-Term Prevention Perspectives

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 13th 2026

FDA accepts sNDA for vosoritide in children with achondroplasia

FDA accepts sNDA for vosoritide in children with achondroplasia

ByMorgan Ebert, Executive Editor

July 13th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FAQ: What does the new "faltering weight" guideline mean for your practice?

PECOS study identifies 20 post-COVID symptoms in children, from fatigue to cardiac and mental health effects

Ultra-processed foods tied to brain differences in young children

Journal Club: Probiotics show promise in reducing GI problems in ASD

Pertussis resurgence: An expert Q&A on diagnostic delays and point-of-care testing